Dr. Paul Sax discusses the largest randomized, controlled trial ever conducted for
Staphylococcus aureus bacteremia in
HIV and ID Observations.
Despite the clinical importance of Staphylococcus aureus bacteremia (SAB), pivotal questions about optimal management have lingered for decades. In the latest HIV and ID Observations, Dr. Paul Sax highlights some studies from the SNAP (Staphylococcus aureus Network Adaptive Platform) trial, an adaptive clinical trial evaluating a broad range of interventions with the goal of improving outcomes for this life-threatening condition.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Follow Via Email box.
Want to see more from NEJM Journal Watch? Register here.